Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Share-based Compensation (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Share-based Compensation for 16 consecutive years, with $324000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 69.23% to $324000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 50.49% decrease, with the full-year FY2024 number at $4.3 million, down 13.2% from a year prior.
  • Share-based Compensation was $324000.0 for Q3 2025 at Harvard Bioscience, down from $472000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q4 2023 to a low of $324000.0 in Q3 2025.
  • A 5-year average of $1.0 million and a median of $1.0 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 46.78% in 2021, then crashed 69.23% in 2025.
  • Harvard Bioscience's Share-based Compensation stood at $1.0 million in 2021, then decreased by 2.23% to $1.0 million in 2022, then soared by 36.83% to $1.4 million in 2023, then plummeted by 30.46% to $961000.0 in 2024, then plummeted by 66.29% to $324000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Share-based Compensation are $324000.0 (Q3 2025), $472000.0 (Q2 2025), and $600000.0 (Q1 2025).